A multicenter, randomized, double-blind trial of a new porcine surfactant in premature infants with respiratory distress syndrome

Objective To compare the efficacy and safety of a new porcine-derived pulmonary surfactant developed by Instituto Butantan with those of animal-derived surfactants commercially available in Brazil, regarding neonatal mortality and the major complications of prematurity in preterm newborns with birth...

Full description

Bibliographic Details
Main Authors: Celso Moura Rebello, Alexander Roberto Precioso, Renata Suman Mascaretti
Format: Article
Language:English
Published: Instituto Israelita de Ensino e Pesquisa Albert Einstein
Series:Einstein (São Paulo)
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082014000400397&lng=en&tlng=en
_version_ 1811326553988005888
author Celso Moura Rebello
Alexander Roberto Precioso
Renata Suman Mascaretti
author_facet Celso Moura Rebello
Alexander Roberto Precioso
Renata Suman Mascaretti
author_sort Celso Moura Rebello
collection DOAJ
description Objective To compare the efficacy and safety of a new porcine-derived pulmonary surfactant developed by Instituto Butantan with those of animal-derived surfactants commercially available in Brazil, regarding neonatal mortality and the major complications of prematurity in preterm newborns with birth weight up to 1500g and diagnosed with respiratory distress syndrome.Methods Neonates diagnosed with respiratory distress syndrome were randomized to receive either Butantan surfactant (Butantan group) or one of the following surfactants: Survanta® or Curosurf®. Newborns receiving Survanta® or Curosurf® comprised the control group. The main outcome measures were mortality rates at 72 hours and at 28 days of life; the typical complications of prematurity as evaluated on the 28th day of life were defined as secundary outcomes.Results No differences were observed between the Butantan (n=154) and control (n=173) groups in relation to birth weight, gestational age, sex, and prenatal use of corticosteroids, or in mortality rates both at 72 hours (14.19% versus 14.12%; p=0.98) and at 28 days (39.86%versus 33.33%; p=0.24) of life. Higher 1- and 5-minute Apgar scores were observed among control group newborns. No differences were observed as regards the secondary outcomes, except for greater need for supplemental oxygen and a higher incidence of interstitial pulmonary emphysema in the Butantan group.Conclusion The mortality rates at 72 hours and 28 days of life and the incidence of major complications of prematurity were comparable to those found with the animal-derived surfactants commercially available in Brazil, showing the efficacy and safety of the new surfactant in the treatment of respiratory distress syndrome in newborns.
first_indexed 2024-04-13T14:51:09Z
format Article
id doaj.art-f30ddbe25c4441d3922cf245bf1cbdc0
institution Directory Open Access Journal
issn 2317-6385
language English
last_indexed 2024-04-13T14:51:09Z
publisher Instituto Israelita de Ensino e Pesquisa Albert Einstein
record_format Article
series Einstein (São Paulo)
spelling doaj.art-f30ddbe25c4441d3922cf245bf1cbdc02022-12-22T02:42:35ZengInstituto Israelita de Ensino e Pesquisa Albert EinsteinEinstein (São Paulo)2317-638512439740410.1590/S1679-45082014AO3095S1679-45082014000400397A multicenter, randomized, double-blind trial of a new porcine surfactant in premature infants with respiratory distress syndromeCelso Moura RebelloAlexander Roberto PreciosoRenata Suman MascarettiObjective To compare the efficacy and safety of a new porcine-derived pulmonary surfactant developed by Instituto Butantan with those of animal-derived surfactants commercially available in Brazil, regarding neonatal mortality and the major complications of prematurity in preterm newborns with birth weight up to 1500g and diagnosed with respiratory distress syndrome.Methods Neonates diagnosed with respiratory distress syndrome were randomized to receive either Butantan surfactant (Butantan group) or one of the following surfactants: Survanta® or Curosurf®. Newborns receiving Survanta® or Curosurf® comprised the control group. The main outcome measures were mortality rates at 72 hours and at 28 days of life; the typical complications of prematurity as evaluated on the 28th day of life were defined as secundary outcomes.Results No differences were observed between the Butantan (n=154) and control (n=173) groups in relation to birth weight, gestational age, sex, and prenatal use of corticosteroids, or in mortality rates both at 72 hours (14.19% versus 14.12%; p=0.98) and at 28 days (39.86%versus 33.33%; p=0.24) of life. Higher 1- and 5-minute Apgar scores were observed among control group newborns. No differences were observed as regards the secondary outcomes, except for greater need for supplemental oxygen and a higher incidence of interstitial pulmonary emphysema in the Butantan group.Conclusion The mortality rates at 72 hours and 28 days of life and the incidence of major complications of prematurity were comparable to those found with the animal-derived surfactants commercially available in Brazil, showing the efficacy and safety of the new surfactant in the treatment of respiratory distress syndrome in newborns.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082014000400397&lng=en&tlng=enSurfactantes pulmonares/uso terapêuticoRecém-nascido de muito baixo pesoRecém-nascidoPrematuroSíndrome do desconforto respiratório do recém-nascido/quimioterapia
spellingShingle Celso Moura Rebello
Alexander Roberto Precioso
Renata Suman Mascaretti
A multicenter, randomized, double-blind trial of a new porcine surfactant in premature infants with respiratory distress syndrome
Einstein (São Paulo)
Surfactantes pulmonares/uso terapêutico
Recém-nascido de muito baixo peso
Recém-nascido
Prematuro
Síndrome do desconforto respiratório do recém-nascido/quimioterapia
title A multicenter, randomized, double-blind trial of a new porcine surfactant in premature infants with respiratory distress syndrome
title_full A multicenter, randomized, double-blind trial of a new porcine surfactant in premature infants with respiratory distress syndrome
title_fullStr A multicenter, randomized, double-blind trial of a new porcine surfactant in premature infants with respiratory distress syndrome
title_full_unstemmed A multicenter, randomized, double-blind trial of a new porcine surfactant in premature infants with respiratory distress syndrome
title_short A multicenter, randomized, double-blind trial of a new porcine surfactant in premature infants with respiratory distress syndrome
title_sort multicenter randomized double blind trial of a new porcine surfactant in premature infants with respiratory distress syndrome
topic Surfactantes pulmonares/uso terapêutico
Recém-nascido de muito baixo peso
Recém-nascido
Prematuro
Síndrome do desconforto respiratório do recém-nascido/quimioterapia
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082014000400397&lng=en&tlng=en
work_keys_str_mv AT celsomourarebello amulticenterrandomizeddoubleblindtrialofanewporcinesurfactantinprematureinfantswithrespiratorydistresssyndrome
AT alexanderrobertoprecioso amulticenterrandomizeddoubleblindtrialofanewporcinesurfactantinprematureinfantswithrespiratorydistresssyndrome
AT renatasumanmascaretti amulticenterrandomizeddoubleblindtrialofanewporcinesurfactantinprematureinfantswithrespiratorydistresssyndrome
AT celsomourarebello multicenterrandomizeddoubleblindtrialofanewporcinesurfactantinprematureinfantswithrespiratorydistresssyndrome
AT alexanderrobertoprecioso multicenterrandomizeddoubleblindtrialofanewporcinesurfactantinprematureinfantswithrespiratorydistresssyndrome
AT renatasumanmascaretti multicenterrandomizeddoubleblindtrialofanewporcinesurfactantinprematureinfantswithrespiratorydistresssyndrome